Biotech Bay

Found 58,296 articles

• Inscopix and Astellas Initiate Collaboration to Study Neural Activity Patterns in Preclinical Models of Psychiatric Disorders

  10/18/2019

  Inscopix has entered into a research collaboration with Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc., to develop novel preclinical drug screening assays for psychiatric disorders.

• Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

  10/18/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive trend vote on the Marketing Authorization Application (MAA) for fostamatinib disodium hexahydrate (fostamatinib)

• Intersect ENT to Report Third Quarter 2019 Financial Results

  10/17/2019

  The company expects to issue the release at approximately 7:30 a.m. ET and management will host a conference call at 8:00 a.m. ET.

• Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference

  10/17/2019

  Lebrikizumab demonstrated dose-dependent improvements across endpoints spanning the range of atopic dermatitis signs and symptoms, including skin lesions and pruritus, when administered once every two or four weeks

• Pulse Biosciences Presents Data From Several Clinical Studies of Nano-Pulse Stimulation Technology™ to Clear Skin Lesions at the 2019 ASDS Annual Meeting

  10/17/2019

  Nano-Pulse Stimulation Technology Highlights Plenary Talk on “Emerging Therapies in Dermatologic Surgery”

• Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications

  10/17/2019

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications.

• Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

  10/17/2019

  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2019 financial results.  

• Penumbra, Inc. Schedules Third Quarter 2019 Earnings Release and Conference Call for November 7, 2019

  10/17/2019

  Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2019 after market close on Thursday, November 7, 2019 at 4:30 PM Eastern Time

• Shockwave Medical to Report Third Quarter 2019 Financial Results on November 7, 2019

  10/17/2019

  Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter 2019 after market close on Thursday, November 7, 2019.

• International Society for Magnetic Resonance in Medicine (ISMRM) Invites MR Radiographers and Technologists to Booth #1303 at RSNA 2019

  10/17/2019

  For more than 25 years, our society has continued to keep magnetic resonance education at the forefront of the healthcare industry. From our year-round, international, multi-day workshops, to the diverse cutting-edge content of our virtual meetings, and our well-established annual meeting, the ISMRM focuses on the latest research and best practices —sharing ideas within an inventive and dynamic community.

• Jennifer Doudna, Ph.D., to be Named Recipient of CLSA’s Life Sciences Leadership Award at 2019 Pantheon DiNA™ Awards

  10/17/2019

  Visionary Leader in CRISPR Gene Editing Technology and Nominee for Nobel Prize in Chemistry to be Honored for Contributions to California’s Life Sciences Sector on Nov. 15

• Thermo Fisher Scientific Launches New External Molecular Control Panel for the Analytical Evaluation of BCR-ABL Test Methods

  10/17/2019

  Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its latest molecular quality control panel.

• Breath Therapeutics, a Zambon company, announces presentations at upcoming scientific conferences

  10/17/2019

   Breath Therapeutics, a Zambon company, a biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need, today announced presentations at three upcoming scientific conferences.

• CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019

  10/17/2019

  CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the third quarter 2019 after the market closes on Thursday, October 31st, 2019.

• The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis

  10/17/2019

  Leaders in atrial fibrillation and wearable technology to develop educational content around atrial fibrillation to help identify and support those at increased risk of stroke

• Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

  10/17/2019

  ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including alcohol use disorder.

• Senti Biosciences Announces Dr. Brenda Cooperstone as New Independent Board Member

  10/17/2019

  Leading gene circuit company recruits experienced drug developer for board of directors’ position to help steward clinical translation of gene circuit therapies

• Mercy Selects Omnicell to Automate and Digitize Medication Management

  10/17/2019

  Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Mercy, one of the top five U.S. health systems that serves Arkansas, Kansas, Missouri and Oklahoma, will support medication management across its service network through Omnicell automation and intelligence solutions.

• ArsenalBio Launches With $85 Million Series A Financing to Advance New Paradigm to Discover and Develop Immune Cell Therapies

  10/17/2019

  Aims to create immune cells with significantly larger DNA payloads encoding synthetic biological instructions to overcome solid tumors’ complex defense systems

• First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma & Symptoms A Majority of Women & Men Report Stigma Around Menstruation; About One in Four Women Report Heavy Menstrual Bleeding

  10/17/2019

  Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by Myovant Sciences, a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Evidation Health, a health and measurement company that helps life sciences companies understand how everyday behavior and health interact.